News Related to Severe Obesity

Related coverage linked through entity extraction aliases.

Rhythm Pharmaceuticals Reports Positive Phase 3 Data for Setmelanotide in Hypothalamic Obesity

Mar 09, 2026

Rhythm Pharmaceuticals announced expanded Phase 3 TRANSCEND trial data showing an 18.8% placebo-adjusted BMI reduction at 52 weeks for setmelanotide in acquired hypothalamic obesity, with FDA PDUFA goal date set for March 20, 2026.

Soleno Therapeutics Updates Prader-Willi Syndrome Launch and European Regulatory Progress

Feb 15, 2026

Soleno Therapeutics provided updates on its VYKAT XR commercial launch for Prader-Willi syndrome, reporting reimbursement progress across nearly 48 Medicaid programs and over 600 prescribers, while European regulatory review continues for approximately 9,500 additional patients.